Expanded Access for 125,000 American Lives for Highly Accurate, Novel Blood Tests
Prevencio, Inc. today announces that Atlas Genomics, Prevencio’s performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencio’s HART tests. The coverage includes HART CVE, the only blood test available for assessing a patient’s one-year risk for a heart attack, stroke, or cardiac death, and HART CADhs for assessing a patient’s risk for significant blockage of a heart artery.
In conjunction with researchers and clinicians at Massachusetts General Hospital, HART test data has been presented at leading cardiology scientific sessions and has been published in peer-review journals. The HART tests are significantly more accurate than single protein blood tests, standard-of-care stress tests, clinical risk scores, and genetic tests. The HART tests are also accurate in patients with diabetes and chronic kidney disease, conditions that often confound other blood-based tests or have contraindications for dye-based imaging, including Cardiac Computed Tomography Angiograms (CCTA).
“Prevencio is grateful for our laboratory partnership with Atlas Genomics and is excited to collaborate with Alivio Health to provide 125,000 Americans with increased access to our precision care HART tests,” said Rhonda Rhyne, Prevencio’s Chief Executive Officer. “Through Alivio Health, we intend to expand awareness, access, reimbursement, and utilization of HART cardiac tests for the benefit of patients. Our mission is ‘preventing the preventable’ by providing patients, clinicians, and employers with personalized tests that are more accurate, safer, and more affordable for preventing, identifying, treating, and monitoring the tens of millions of patients with cardiac issues.”
Cardiovascular disease is the leading cause of death in the U.S. and globally. According to the American Heart Association, the U.S. spends approximately $316 billion annually on cardiovascular disease and stroke, or approximately 10% of the $3.2 trillion spent on total healthcare. By 2030, more than 40% of the U.S. adult population is projected to have cardiovascular disease. For additional information, visit Prevencio, Inc.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
